(E)-4-cyclohexyl-2-buten-1-ol | 1589-44-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-4-cyclohexyl-2-buten-1-ol
• 英文别名: (2E)-4-cyclohexyl-2-buten-1-ol；(E)-4-cyclohexylbut-2-en-1-ol；trans-4-Cyclohexyl-but-2-en-1-ol；trans-4-cyclohexyl-2-buten-1-ol；(E)-4-cyclohexyl-2-butenol
• CAS: 1589-44-2
• 化学式: C₁₀H₁₈O
• 分子量: 154.252
• InChiKey: IXFHCABRYGXWSU-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-4-cyclohexyl-2-buten-1-ol 在 titanium(IV) isopropylate 、 叔丁基过氧化氢 、 L-(+)-酒石酸二乙酯 作用下， 以 异辛烷 、 二氯甲烷 为溶剂， 反应 24.0h， 以80%的产率得到(2S,3S)-4-cyclohexyl-2,3-epoxy-1-butanol
  参考文献：
  名称：

  Stereoselective Preparation of Syn α-Hydroxy-β-amino Ester Units via Regioselective Opening of α,β-Epoxy Esters:  Enantioselective Synthesis of Taxol C-13 Side Chain and Cyclohexylnorstatine

  摘要：

  DOI：

  10.1021/jo951441h
• 作为产物：
  描述：

  ethyl (E)-4-cyclohexylbut-2-enoate 在 二异丁基氢化铝 作用下， 以 乙醚 为溶剂， 以96%的产率得到(E)-4-cyclohexyl-2-buten-1-ol
  参考文献：
  名称：

  N - Boc-氨基烷基环氧化物的对映选择性合成的便利立体异构方法

  摘要：

  已经开发了N - Boc-氨基烷基环氧化物的有效，立体发散和对映选择性的合成。从对映异构体富集的抗N-二苯基甲基-3-氨基-1,2-二醇开始，并在改变氮保护基团之后，分子内的Mitsunobu反应导致赤型氨基烷基环氧化物；由伯醇的保护，仲醇的活化和同时的脱保护/环化组成的三个步骤序列以良好的产率提供了相应的苏式异构体。

  DOI：

  10.1016/0040-4039(95)00415-9

文献信息

• Reaction of silyl ketene acetals with epoxides: a new method for the synthesis of γ-butanolides
  作者：Veselin Maslak、Radomir Matović、Radomir N. Saičić

  DOI：10.1016/j.tet.2004.07.007

  日期：2004.9

  Titanium tetrachloride promoted reaction of silyl ketene acetals with epoxides, followed by acidic work-up, affords butanolides in moderate/good yields. With epihalohydrins the reaction is regioselective and occurs at the less substituted end of the epoxide; the γ-haloalkyl-γ-butanolides thus obtained can be further transformed into various products.

  四氯化钛促进了甲硅烷基乙烯酮缩醛与环氧化物的反应，然后进行酸性处理，以中等/良好的收率得到丁醇化物。与表卤代醇反应是区域选择性的，发生在环氧化物的取代度较低的末端。由此获得的γ-卤代烷基-γ-丁醇化物可以进一步转化为各种产物。
• Compounds as inhibitor of tumor necrosis factor alpha release
  申请人：Hoffmann-La Roche Inc.

  公开号：US06239151B1

  公开（公告）日：2001-05-29

  The invention provides hydrazine derivatives of the formula wherein R1 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R2 is an acyl group derived from an &agr;-, &bgr;-, &ggr;- or &dgr;-(amino, hydroxy or thiol)carboxylic acid in which the amino, hydroxy or thiol group is optionally lower alkylated or the amino group is optionally acylated, sulphonylated or amidated and in which any functional group present in a side-chain is optionally protected, or a group of the formula Het(CH2)mCO; R3 is hydrogen, lower alkyl, halo-lower alkyl, cyano-lower alkyl, amino-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, heterocyclyl-lower alkyl, heterocyclylcarbonyl-lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl-lower alkenyl, aryl or heterocyclyl; R4 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a grouping of the formula X-aryl, X-heteroaryl or —(CH2)n—CH═CR5R6; R5 and R6 together are lower alkylene in which one CH2 group is optionally replaced by a hetero atom; Het is heterocyclyl; X is a spacer group; m is 0, 1, 2, 3 or 4; and n is 1 or 2; and their pharmaceutically acceptable salts inhibit the release of tumour necrosis factor alpha (TNF-&agr;) from cells. They can be used as medicaments, especially in the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumours, cachexia, cardiovascular diseases, fever, haemorrhage and sepsis.

  该发明提供了以下结构的肼衍生物 其中R1是较低的烷基、较低的烯基、较低的环烷基、较低的环烷基-较低的烷基、芳基或芳基-较低的烷基；R2是从α-、β-、γ-或δ-(氨基、羟基或硫醇)羧酸衍生的酰基，其中氨基、羟基或硫醇基可选择性地被较低的烷基化，或氨基可选择性地被酰化、磺酰化或酰胺化，并且侧链中存在的任何官能团可选择性地被保护，或者是Het(CH2)mCO的结构；R3是氢、较低的烷基、卤代较低的烷基、氰基-较低的烷基、氨基-较低的烷基、羟基-较低的烷基、较低的烷氧基-较低的烷基、较低的烷氧羰基-较低的烷基、较低的环烷基-较低的烷基、芳基-较低的烷基、杂环烷基-较低的烷基、杂环烷基羰基-较低的烷基、较低的烯基、较低的炔基、较低的环烷基、芳基-较低的烯基、芳基或杂环烷基；R4是较低的烷基、较低的烯基、较低的环烷基、较低的环烷基-较低的烷基或X-芳基、X-杂环芳基或—( )n—CH=CR5R6的结构；R5和R6一起是较低的烷基，其中一个 基可选择性地被杂原子取代；Het是杂环烷基；X是间隔基；m为0、1、2、3或4；n为1或2；它们的药学上可接受的盐抑制肿瘤坏死因子α(TNF-α)从细胞中释放。它们可用作药物，特别是用于治疗炎症和自身免疫性疾病、骨关节炎、呼吸道疾病、肿瘤、消瘦症、心血管疾病、发热、出血和败血症。
• Enantioselective Synthesis of Allylboronates Bearing a Tertiary or Quaternary B-Substituted Stereogenic Carbon by NHC-Cu-Catalyzed Substitution Reactions
  作者：Aikomari Guzman-Martinez、Amir H. Hoveyda

  DOI：10.1021/ja104254d

  日期：2010.8.11

  Allylic substitutions that afford alpha-substituted allylboronates bearing B-substituted tertiary or quaternary carbon stereogenic centers are presented. C-B bond-forming reactions, catalyzed by chiral bidentate Cu-NHC complexes, are performed in the presence of commercially available bis(pinacolato)diboron. Transformations proceed in high yield (up to >98%) and site selectivity (>98% S(N)2'), and

  提供带有 B 取代的叔或季碳立体中心的 α 取代的烯丙基硼酸酯的烯丙基取代。由手性双齿 Cu-NHC 配合物催化的 CB 键形成反应在市售的双（频哪醇）二硼存在下进行。转化以高产率（高达 >98%）和位点选择性（>98% S(N)2'）以及高达 >99:1 的对映体比例进行。可以使用反式或顺式二取代的烯烃；烷基-（直链和支链）和芳基-三取代的烯丙基碳酸酯用作有效的底物。带有季碳中心的烯丙基硼酸酯在空气中是稳定的，可以很容易地通过硅胶色谱法纯化；相比之下，仲烯丙基硼酸酯不能以相同的方式纯化并且稳定性明显较差。
• Photoredox/Nickel-Catalyzed Single-Electron Tsuji-Trost Reaction: Development and Mechanistic Insights
  作者：Jennifer K. Matsui、Álvaro Gutiérrez-Bonet、Madeline Rotella、Rauful Alam、Osvaldo Gutierrez、Gary A. Molander

  DOI：10.1002/anie.201809919

  日期：2018.11.26

  variety of linear allylic alcohols and allylated monosaccharides are accessible in high yields under mild reaction conditions. Quantum mechanical calculations [DFT and DLPNO‐CCSD(T)] support the mechanistic hypothesis of a Ni0 to NiII oxidative addition pathway followed by radical addition and inner‐sphere allylation.

  公开了区域选择性的，镍催化的仲，苄基和α-烷氧基自由基前体的光氧化还原烯丙基化。通过该歧管，可以在温和的反应条件下以高收率获得各种直链烯丙基醇和烯丙基化单糖。量子力学计算[DFT和DLPNO-CCSD（T）]支持Ni 0到Ni II氧化加成途径继之以自由基加成和内球烯丙基化的机理假说。
• A Catalytic Asymmetric Chlorocyclization of Unsaturated Amides
  作者：Arvind Jaganathan、Atefeh Garzan、Daniel C. Whitehead、Richard J. Staples、Babak Borhan

  DOI：10.1002/anie.201006910

  日期：2011.3.7

  The asymmetric chlorocyclization of unsaturated amides catalyzed by (DHQD)2PHAL yields oxazoline and dihydrooxazine derivatives (see scheme). The reaction is operationally simple and employs 1–2 mol % of the commercially available (DHQD)2PHAL (hydroquinidine 1,4‐phthalazinediyl diether) catalyst. Different substitution patterns of the olefin as well as aromatic and aliphatic olefin substituents are

  （DHQD）2 PHAL催化不饱和酰胺的不对称氯环化反应，生成恶唑啉和二氢恶嗪衍生物（参见方案）。该反应操作简单，并使用1-2 mol％的市售（DHQD）2 PHAL（氢奎尼丁1,4-萘二甲酰二醚）催化剂。烯烃以及芳族和脂族烯烃取代基的不同取代方式具有良好的耐受性。DCDPH = N，N-二氯-5,5-二苯基乙内酰脲。